Small Molecules
20 September 2013
Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement20 September 2013
Cyclacel’s Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer20 September 2013
TauRx achieves milestone in global Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease20 September 2013
RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD19 September 2013
Omeros Reports Initiation of Phase 2 Clinical Trial with OMS82418 September 2013
FDA accepts new drug application for investigational compound Epanova for the treatment of severe hypertriglyceridaemia18 September 2013
Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients18 September 2013
GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy17 September 2013
FDA Approves Teva’s TREANDA® (bendamustine HCI) Injection, a New Liquid Formulation17 September 2013
Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-443017 September 2013
Sunovion Reports Eslicarbazepine Acetate Meets Primary Endpoint in Two Phase 3 Monotherapy Studies for Partial-onset Seizures in Adults with Epilepsy17 September 2013
Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)17 September 2013
Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia17 September 2013
KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Results for the Reduction of Submental Fat16 September 2013
GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma16 September 2013
Ultragenyx Announces Positive Data From Retrospective Study of UX007 Triheptanoin in Patients With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)16 September 2013
Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients16 September 2013
NovaBay Pharmaceuticals Announces Positive Results from Phase 2 Clinical Study of Auriclosene to Reduce Urinary Catheter Blockage and Encrustation14 September 2013
PharmaMar Announces Top line Results for PM01183 Phase II trial in Patients with Platinum Resistant/Refractory Ovarian Cancer13 September 2013
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-113 September 2013
Gilead’s Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase 2 Study12 September 2013
Omeros Reports Additional Positive Results from OMS824 Program12 September 2013
Fedora Pharmaceuticals Demonstrates that FPI-1465 Increases Activity of Certain Antibiotics against Drug-Resistant Bacteria12 September 2013
iCeutica Announces Positive Top-line Phase 1 Results for ICE 1201 Metaxalone Program12 September 2013
Raptor Pharmaceutical Receives Marketing Authorization for PROCYSBI(R) in European UnionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports